MNMD Earnings

MNMD reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was -0.78, surpassing the expected -0.52 by -50%. The stock experienced a 3.17% price change on the earnings day and a 7.05% change over the next five days, reflecting market reactions to the results.

Following MNMD's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 3.17% on the day of the release. Over the subsequent five days, it saw a 7.05% change. Historically, MNMD's stock price tends to shift by an average of 3.34% in the 10 days leading up to earnings and 1.74% in the 10 days following, providing insight into potential market.

For , analysts estimate MNMD's annual revenue to reach undefined, while the EPS is projected at -0.48. These estimates reflect recent revisions, with revenue estimates revised upward by 25.8% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MNMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised upward by 25.8%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MNMD's stock price typically moves by 3.34% in the 10 days before its earnings and 1.74% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.48 and revenue of undefined.

The earnings call summary highlights strong financial health, promising Phase III trials, and significant market opportunities for MM120 ODT. The Q&A section reveals enthusiasm from KOLs and psychiatrists, and no major negative concerns were raised. While some management responses were unclear, overall sentiment remains positive, particularly with strategic commercial readiness and financial stability. Adjustments for potential positive catalysts, like new partnerships or optimistic guidance, were not applicable. Given the company's robust position, a positive stock price movement (2% to 8%) is expected over the next two weeks.